Table 1.
Demographic and clinical characteristics
| Age, years | 52.0 (14.5) |
|---|---|
| Women, n (%) | 51 (50 %) |
| Ethnicity, n (%) | |
| Chinese | 70 (69 %) |
| Malay | 11 (11 %) |
| Indian | 15 (15 %) |
| Caucasian | 0 (0 %) |
| Other | 5 (5 %) |
| Body Mass Index, Kg/m2 | 27.2 (5.4) |
| Smokers, n (%) | 14 (14 %) |
| Disease duration, years | 9.3 (0.3) |
| Disease type, n (%) | |
| • Rheumatoid arthritis | 46 (46 %) |
| • Gout | 31 (31 %) |
| • Spondyloarthritis | 15 (15 %) |
| • Psoriatic arthritis | 4 (4 %) |
| • Undifferentiated inflammatory arthritis | 5 (5 %) |
| Medications, n (%) | |
| • Methotrexate | 42 (60 %) |
| • Combination DMARD therapy (≥2 DMARDs) | 52 (74 %) |
| • Biologics | 4 (6 %) |
| • Prednisone | 40 (40 %) |
| Other medications, n (%) | |
| NSAID, n (%) | 49 (49 %) |
| Diabetes Mellitus, n (%) | 12 (12 %) |
| Patient global VAS (VAS 0–100), mm | 26 (26) |
| Tender (28) joint count | 1.8 (2.8) |
| Swollen (28) joint count | 1.3 (2.1) |
| DAS28-ESR score | 3.54 (1.1) |
| ESR, mm/h | 31.6 (21.2) |
| CRP, mg/L | 27.4 (32.2) |
| mHAQ score | 0.25 (0.36) |
Data presented as mean (SD) unless specified
DMARD Disease modifying anti-rheumatic drug, NSAID Non steroidal anti-inflamamtory drugs, VAS Visual analogue scale, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, DAS-28 disease activity score in 28 joints